Q4 2020 Excelsior Newsletter November 30, 2020:Where We Are Today And When Will New Vaccines Be Approved? by Bob Kordella, R.Ph., MBA, Chief Clinical Officer Worldwide there were 48 Read More »
Q3 2020 Excelsior Newsletter COVID-19 Vaccine Update by Bob Kordella, R.Ph., MBA, Chief Clinical Officer As several COVID-19 Read More »
Q2 2020 Excelsior Newsletter The Rebate Bubble by Jonalan Smith, PharmD, FASCP, Senior Vice President Everyone knows the Read More »
Q1 2020 Excelsior Newsletter The Impact Of Humira Citrate-Free by Bob Kordella, R.Ph., MBA Humira is typically in Read More »
Q4 2019 Excelsior Newsletter HIV PrEP Therapies by Darian Hurst, Vice President In June 2019, the United States Read More »
Q3 2019 Excelsior Newsletter Specialty Drug Manufacturer Assistance Programs And Your Plan by Sarah Martin, ASA, MAAA, FCA, Read More »
Q2 2019 Excelsior Newsletter Psychosocial Barriers Affecting Medication Adherence; the Importance of the Provider/Patient Relationship by Clay Keene, Vice Read More »
Q1 2019 Excelsior Newsletter What is the Purpose of the Drug Watch List? by Bob Kordella, RPh, MBA, Read More »
Q4 2018 Excelsior Newsletter A Primer on Specialty Drug Spend Under the Medical Benefit by Sarah Martin, ASA, Read More »